View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: June 28, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 Un...

Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference REDWOOD CITY, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today highlighted new data on VYKATTM XR (diazoxide choline) extended-release tablets, previously known as DCCR, at the 2025 United in Hope: International Prader-Willi Syndrome Conference. “We believe that these data reveal critical insights on the potential...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: June 21, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Soleno Therapeutics Announces Multiple Presentations at the 2025 Unite...

Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research, and the International Prader-Willi Syndrome Organisation REDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced one oral and six poster presentatio...

 PRESS RELEASE

Reed’s to Participate in OTC Markets Virtual Investor Conference on Ju...

Reed’s to Participate in OTC Markets Virtual Investor Conference on June 26 NORWALK, Conn., June 18, 2025 (GLOBE NEWSWIRE) -- Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced its participation in the upcoming OTC Markets Virtual Investor Conference on Thursday, June 26, 2025. Reed’s management team will hold virtual 1x1 meetings throughout the day and host a presentation at 2:00pm ET. This will be a live, interactive event where investors are invited to ask the Company questions in re...

 PRESS RELEASE

Soleno Therapeutics Announces Submission and EMA Validation of Marketi...

Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno’s Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DC...

Assured Guaranty Ltd: 1 director

A director at Assured Guaranty Ltd sold 82,355 shares at 86.113USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

 PRESS RELEASE

Soleno Therapeutics to Participate in Upcoming June Conferences

Soleno Therapeutics to Participate in Upcoming June Conferences REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in June: Jefferies Global Healthcare ConferencePresentation Date: Wednesday, June 4, 2025 at 10:30 AM ETPresentation Format: Corporate PresentationWebcast:  Goldman Sachs 46th Healthcare ConferencePresentation Date: Tuesday, June 10, 2025 at 8:40 A...

 PRESS RELEASE

Soleno Therapeutics Announces Data Presentation Showing that Resumptio...

Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome REDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced data presented from its clinical development program of VYKAT™ XR (diazoxide choline) extended-release tablets, previousl...

 PRESS RELEASE

Dorchester Minerals, L.P. Announces Retirement and Appointment to the ...

Dorchester Minerals, L.P. Announces Retirement and Appointment to the Board of Managers DALLAS, May 19, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP). As previously announced, Ron Trout retired as an Independent Manager of the Partnership after the conclusion of his term, which ended immediately following the 2025 Annual Meeting. Casey McManemin, Chairman of the Board, stated “I would like to thank Ron for 17 years of dedicated service to the Board of Managers. His business acumen and insights have made a meaningful contribution to the Board.” In ...

 PRESS RELEASE

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in ...

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 REDWOOD CITY, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced poster presentations from its VYKATTM XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, clinical development program for the treatment of hyperphagia associated PWS at the Pediatric Endocrine Society (PES) Meeting 2025, which is being held May ...

 PRESS RELEASE

Reed’s Reports First Quarter 2025 Results

Reed’s Reports First Quarter 2025 Results Management to Host Conference Call Tomorrow at 8:30 a.m. ET NORWALK, Conn., May 13, 2025 (GLOBE NEWSWIRE) -- Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, is reporting financial results for the three months ended March 31, 2025. Q1 2025 Financial Highlights (vs. Q1 2024): Net sales increased 4.5% to $10.0 million.Gross profit remained flat at $3.4 million, with gross margin of 33.9% compared to 35.6%.Delivery and handling costs were $3.13 per case c...

 PRESS RELEASE

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in ...

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data on the burden of Prader-Willi syndrome (PWS) and findings from its clinical development program of VYKAT™ XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia associated PWS at the Inter...

Cadence Bank: 1 director

A director at Cadence Bank sold 25,060 shares at 30.040USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

 PRESS RELEASE

Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) X...

Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025 REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data from its VYKATTM XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, clinical development program for the treatment of hyperphagia associated with Prader-Willi syndrome (PWS) at the Joint Congress of Europe...

 PRESS RELEASE

Dorchester Minerals, L.P. Announces First Quarter Results

Dorchester Minerals, L.P. Announces First Quarter Results DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership’s net income for the quarter ended March 31, 2025 of $17,642,000, or $0.36 per common unit. A comparison of the Partnership’s consolidated results for the quarter ended March 31, 2025 and 2024 are set forth below:   Three Months Ended  March 31,  2025 2024Operating Revenues $43,164,000  $30,979,000Net Income $17,642,000  $18,167,000Net Income Per Common Unit $0.36  $0.44         The Partnership previ...

 PRESS RELEASE

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and...

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Recent Corporate Highlights Announced U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline...

 PRESS RELEASE

Reed’s Launches New Multifunctional Soda Line with 4 Bold Flavors

Reed’s Launches New Multifunctional Soda Line with 4 Bold Flavors Bringing Fresh, Organic Ginger & Functional Ingredients to the Modern Wellness Space NORWALK, Conn., May 06, 2025 (GLOBE NEWSWIRE) -- Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, is thrilled to introduce its all-new Multifunctional Soda Line, redefining refreshment with delicious flavors, powerful ingredients, and a smarter way to sip. This new line features four innovative flavors: Berry Bubbly, Strawberry Vanilla, Root Beer, and...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 3, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch